



## Medium-dose ICS

■ Phase 2b: placebo/dupilumab ■ Phase 2b: dupilumab/dupilumab ■ QUEST: placebo/dupilumab ■ QUEST: dupilumab/dupilumab


### (A) Exposed population



### (B) $\geq 150$ eosinophils/ $\mu$ L at PSBL



### (C) $\geq 300$ eosinophils/ $\mu$ L at PSBL



### (D) FeNO $\geq 25$ ppb at PSBL

